Ataxia Telangiectasia
Quince Therapeutics S.p.A. focuses its clinical research on Ataxia Telangiectasia and the associated neurological burden of this rare genetic disorder, with particular attention to central nervous system symptoms and functional impairment in children.
- CNS symptoms
- Neurological dysfunction
- Rare disease care
The sponsor’s research activity in this area is directed toward understanding and addressing the motor and neurological manifestations of Ataxia Telangiectasia.
Neurology
The clinical portfolio places strong emphasis on neurology, especially measures of disease-related movement and coordination deficits, with outcomes centered on changes in neurological performance and symptom burden.
- Motor coordination
- Neurological assessment
- Functional impairment
This area reflects an interest in therapies aimed at improving everyday neurological function in patients affected by progressive central nervous system involvement.
Pediatric rare disease
Quince Therapeutics S.p.A. is active in pediatric rare disease research, with studies involving young participants and a focus on age-specific disease expression in Ataxia Telangiectasia.
- Pediatric patients
- Rare neurological disorders
- Childhood-onset disease
The sponsor’s clinical interest includes the needs of children living with chronic, disabling neurogenetic conditions.
Safety and tolerability
Alongside therapeutic effect, the sponsor’s trials address safety and tolerability in Ataxia Telangiectasia, supporting evaluation of treatment use in a vulnerable patient population.
- Safety monitoring
- Tolerability
- Long-term treatment use
Its research landscape also includes extension-focused clinical activity in neurological rare disease management.
